{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:13:11Z","timestamp":1784052791337,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00428-026-04440-2","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:45:09Z","timestamp":1771289109000},"page":"135-144","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Utility of RB1 immunohistochemistry for prognostic subtyping of pulmonary large cell neuroendocrine carcinoma"],"prefix":"10.1007","volume":"489","author":[{"given":"Michael","family":"Minkley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kashif","family":"Ravasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi","family":"Nghiem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxia","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Churg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7799-7860","authenticated-orcid":false,"given":"Julia R.","family":"Naso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"4440_CR1","unstructured":"Rekhtman N, Scagliotti GV, Osamura RY, et al (2021) Large cell neuroendocrine carcinoma of the lung. In: WHO Classification of Tumors Editorial Board: Thoracic Tumours, 5th ed. Lyon (France): International Agency for Research on Cancer. (WHO classification of tumours series, 5th ed.; vol. 5). https:\/\/publications.iarc.fr\/595."},{"key":"4440_CR2","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/s41416-021-01407-9","volume":"125","author":"CR Lindsay","year":"2021","unstructured":"Lindsay CR, Shaw EC, Moore DA et al (2021) Large cell neuroendocrine lung carcinoma: consensus statement from the British Thoracic Oncology Group and the Association of Pulmonary Pathologists. Br J Cancer 125:1210\u20131216. https:\/\/doi.org\/10.1038\/s41416-021-01407-9","journal-title":"Br J Cancer"},{"key":"4440_CR3","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1158\/1078-0432.CCR-15-2946","volume":"22","author":"N Rekhtman","year":"2016","unstructured":"Rekhtman N, Pietanza MC, Hellmann MD et al (2016) Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. Clin Cancer Res 22:3618\u20133629. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2946","journal-title":"Clin Cancer Res"},{"key":"4440_CR4","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","volume":"14","author":"M Offin","year":"2019","unstructured":"Offin M, Chan JM, Tenet M et al (2019) Concurrent RB1 and TP53 alterations define a\u00a0subset of EGFR-mutant lung cancers at risk for\u00a0histologic transformation and inferior clinical outcomes. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 14:1784\u20131793. https:\/\/doi.org\/10.1016\/j.jtho.2019.06.002","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"4440_CR5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.15","author":"J Wang","year":"2020","unstructured":"Wang J, Chen G, Zhang B et al (2020) Concurrent somatic alterations of TP53 and RB1 in Chinese lung adenocarcinoma with or without EGFR mutations. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2020.38.15","journal-title":"J Clin Oncol"},{"key":"4440_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","volume":"524","author":"J George","year":"2015","unstructured":"George J, Lim JS, Jang SJ et al (2015) Comprehensive genomic profiles of small cell lung cancer. Nature 524:47\u201353. https:\/\/doi.org\/10.1038\/nature14664","journal-title":"Nature"},{"key":"4440_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1449490","volume":"14","author":"K Kang","year":"2024","unstructured":"Kang K, Li B, Wang S et al (2024) Clinical characteristics and treatment management of combined large cell neuroendocrine carcinoma, a subtype of large cell neuroendocrine carcinoma. Front Oncol 14:1449490. https:\/\/doi.org\/10.3389\/fonc.2024.1449490","journal-title":"Front Oncol"},{"key":"4440_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.667468","volume":"11","author":"T Atieh","year":"2021","unstructured":"Atieh T, Huang CH (2021) Treatment of advanced-stage large cell neuroendocrine cancer (LCNEC) of the lung: a tale of two diseases. Front Oncol 11:667468. https:\/\/doi.org\/10.3389\/fonc.2021.667468","journal-title":"Front Oncol"},{"key":"4440_CR9","doi-asserted-by":"publisher","first-page":"7218","DOI":"10.3390\/curroncol30080523","volume":"30","author":"C Buium","year":"2023","unstructured":"Buium C, Negru S, Ionescu DN, Dediu M (2023) The unmet diagnostic and treatment needs in large cell neuroendocrine carcinoma of the lung. Curr Oncol Tor Ont 30:7218\u20137228. https:\/\/doi.org\/10.3390\/curroncol30080523","journal-title":"Curr Oncol Tor Ont"},{"key":"4440_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.650293","volume":"11","author":"MG Ferrara","year":"2021","unstructured":"Ferrara MG, Stefani A, Simbolo M et al (2021) Large cell neuro-endocrine carcinoma of the lung: current treatment options and potential future opportunities. Front Oncol 11:650293. https:\/\/doi.org\/10.3389\/fonc.2021.650293","journal-title":"Front Oncol"},{"key":"4440_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1158\/1078-0432.CCR-17-1921","volume":"24","author":"JL Derks","year":"2018","unstructured":"Derks JL, Leblay N, Thunnissen E et al (2018) Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome. Clin Cancer Res 24:33\u201342. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1921","journal-title":"Clin Cancer Res"},{"key":"4440_CR12","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1158\/1078-0432.CCR-19-0556","volume":"26","author":"M Zhuo","year":"2020","unstructured":"Zhuo M, Guan Y, Yang X et al (2020) The prognostic and therapeutic role of genomic subtyping by sequencing tumor or cell-free DNA in pulmonary large-cell neuroendocrine carcinoma. Clin Cancer Res 26:892\u2013901. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0556","journal-title":"Clin Cancer Res"},{"key":"4440_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6834","volume":"13","author":"Z Wang","year":"2024","unstructured":"Wang Z, Wu Y, Lu T et al (2024) The outcomes of different regimens depend on the molecular subtypes of pulmonary large-cell neuroendocrine carcinoma: a retrospective study in China. Cancer Med 13:e6834. https:\/\/doi.org\/10.1002\/cam4.6834","journal-title":"Cancer Med"},{"key":"4440_CR14","doi-asserted-by":"publisher","first-page":"4395","DOI":"10.1007\/s00330-024-11345-8","volume":"35","author":"G Argentieri","year":"2025","unstructured":"Argentieri G, Valsecchi C, Petrella F et al (2025) Implementation of the 9th TNM for lung cancer: practical insights for radiologists. Eur Radiol 35:4395\u20134402. https:\/\/doi.org\/10.1007\/s00330-024-11345-8","journal-title":"Eur Radiol"},{"key":"4440_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"4440_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41379-021-00920-9","volume":"35","author":"JR Naso","year":"2022","unstructured":"Naso JR, Tessier-Cloutier B, Senz J et al (2022) Significance of p53 immunostaining in mesothelial proliferations and correlation with TP53 mutation status. Mod Pathol 35:77\u201381. https:\/\/doi.org\/10.1038\/s41379-021-00920-9","journal-title":"Mod Pathol"},{"key":"4440_CR17","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/path.5375","volume":"250","author":"N Singh","year":"2020","unstructured":"Singh N, Piskorz AM, Bosse T et al (2020) p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. J Pathol 250:336\u2013345. https:\/\/doi.org\/10.1002\/path.5375","journal-title":"J Pathol"},{"key":"4440_CR18","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.1158\/1078-0432.CCR-22-1115","volume":"28","author":"CA Febres-Aldana","year":"2022","unstructured":"Febres-Aldana CA, Chang JC, Ptashkin R et al (2022) Rb tumor suppressor in small cell lung cancer: combined genomic and IHC analysis with a description of a distinct Rb-proficient subset. Clin Cancer Res 28:4702\u20134713. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1115","journal-title":"Clin Cancer Res"},{"key":"4440_CR19","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM et al (2021) PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 372:n160. https:\/\/doi.org\/10.1136\/bmj.n160","journal-title":"BMJ"},{"key":"4440_CR20","unstructured":"R Core Team (2019) A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/"},{"key":"4440_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/fmch-2019-000262","volume":"8","author":"MZI Chowdhury","year":"2020","unstructured":"Chowdhury MZI, Turin TC (2020) Variable selection strategies and its importance in clinical prediction modelling. Fam Med Community Health 8:e000262. https:\/\/doi.org\/10.1136\/fmch-2019-000262","journal-title":"Fam Med Community Health"},{"key":"4440_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.humpath.2023.09.002","volume":"142","author":"H Wang","year":"2023","unstructured":"Wang H, Yan L, Zhu Y et al (2023) Exploring the molecular features and genetic prognostic factors of pulmonary high-grade neuroendocrine carcinomas. Hum Pathol 142:81\u201389. https:\/\/doi.org\/10.1016\/j.humpath.2023.09.002","journal-title":"Hum Pathol"},{"key":"4440_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.653153","volume":"11","author":"H Saghaeiannejad Esfahani","year":"2021","unstructured":"Saghaeiannejad Esfahani H, Vela CM, Chauhan A (2021) Prevalence of TP-53\/Rb-1 co-mutation in large cell neuroendocrine carcinoma. Front Oncol 11:653153. https:\/\/doi.org\/10.3389\/fonc.2021.653153","journal-title":"Front Oncol"},{"key":"4440_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.664397","volume":"11","author":"Y Chen","year":"2021","unstructured":"Chen Y, Cui X, Wang D et al (2021) Molecular characterization and prognostication of large cell neuroendocrine carcinoma and large cell carcinoma. Front Oncol 11:664397. https:\/\/doi.org\/10.3389\/fonc.2021.664397","journal-title":"Front Oncol"},{"key":"4440_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107825","volume":"192","author":"M Li","year":"2024","unstructured":"Li M, Zhang Y, Zhou P et al (2024) Mutational analysis of pulmonary large cell neuroendocrine carcinoma: APC gene mutations identify a good prognostic factor. Lung Cancer 192:107825. https:\/\/doi.org\/10.1016\/j.lungcan.2024.107825","journal-title":"Lung Cancer"},{"key":"4440_CR26","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1093\/oncolo\/oyab044","volume":"27","author":"W Peng","year":"2022","unstructured":"Peng W, Cao L, Chen L et al (2022) Comprehensive characterization of the genomic landscape in Chinese pulmonary neuroendocrine tumors reveals prognostic and therapeutic markers (CSWOG-1901). Oncologist 27:e116\u2013e125. https:\/\/doi.org\/10.1093\/oncolo\/oyab044","journal-title":"Oncologist"},{"key":"4440_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejca.2021.04.030","volume":"152","author":"J Hadoux","year":"2021","unstructured":"Hadoux J, Kanaan C, Durand A et al (2021) Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: results from the multicentre RBNEC study of the Groupe d\u2019Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network. Eur J Cancer 152:100\u2013115. https:\/\/doi.org\/10.1016\/j.ejca.2021.04.030","journal-title":"Eur J Cancer"},{"key":"4440_CR28","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.7150\/jca.84600","volume":"14","author":"W Yang","year":"2023","unstructured":"Yang W, Wang W, Li Z et al (2023) Differences between advanced large cell neuroendocrine carcinoma and advanced small cell lung cancer: a propensity score matching analysis. J Cancer 14:1541\u20131552. https:\/\/doi.org\/10.7150\/jca.84600","journal-title":"J Cancer"},{"key":"4440_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10797-3","volume":"23","author":"L Huang","year":"2023","unstructured":"Huang L, Feng Y, Xie T et al (2023) Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer. BMC Cancer 23:312. https:\/\/doi.org\/10.1186\/s12885-023-10797-3","journal-title":"BMC Cancer"},{"key":"4440_CR30","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.21037\/jtd-2025-345","volume":"17","author":"Y Mao","year":"2025","unstructured":"Mao Y, Chang H, Wang L et al (2025) Comparison of clinicopathologic features and prognosis between surgically resected pulmonary large-cell neuroendocrine carcinoma and small-cell lung cancer. J Thorac Dis 17:2394\u20132410. https:\/\/doi.org\/10.21037\/jtd-2025-345","journal-title":"J Thorac Dis"},{"key":"4440_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/1758834013517413","volume":"6","author":"N Asai","year":"2014","unstructured":"Asai N, Ohkuni Y, Kaneko N et al (2014) Relapsed small cell lung cancer: treatment options and latest developments. Ther Adv Med Oncol 6:69\u201382. https:\/\/doi.org\/10.1177\/1758834013517413","journal-title":"Ther Adv Med Oncol"},{"key":"4440_CR32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.21873\/anticanres.17417","volume":"45","author":"K Yoshida","year":"2025","unstructured":"Yoshida K, Watanabe K, Nishimura T et al (2025) Improvement in survival in patients with advanced non-small cell lung cancer. Anticancer Res 45:295\u2013305. https:\/\/doi.org\/10.21873\/anticanres.17417","journal-title":"Anticancer Res"},{"key":"4440_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108453","volume":"202","author":"H Satoh","year":"2025","unstructured":"Satoh H, Okuma Y, Shinno Y et al (2025) Evolving treatments and prognosis in stage IV non-small cell lung cancer: 20 years of progress of novel therapies. Lung Cancer 202:108453. https:\/\/doi.org\/10.1016\/j.lungcan.2025.108453","journal-title":"Lung Cancer"},{"key":"4440_CR34","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1001\/jamaoncol.2022.6901","volume":"9","author":"T Voruganti","year":"2023","unstructured":"Voruganti T, Soulos PR, Mamtani R et al (2023) Association between age and survival trends in advanced non-small cell lung cancer after adoption of immunotherapy. JAMA Oncol 9:334\u2013341. https:\/\/doi.org\/10.1001\/jamaoncol.2022.6901","journal-title":"JAMA Oncol"},{"key":"4440_CR35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.21873\/invivo.11783","volume":"34","author":"M Bratova","year":"2020","unstructured":"Bratova M, Karlinova B, Skrickova J et al (2020) Non-small cell lung cancer as a chronic disease - a prospective study from the Czech TULUNG Registry. In Vivo 34:369\u2013379. https:\/\/doi.org\/10.21873\/invivo.11783","journal-title":"In Vivo"},{"key":"4440_CR36","unstructured":"National Library of Medicine (U.S.). (2023) Next generation sequencing-based stratification of front line treatment of high grade neuroendocrine carcinoma (PRECISION-NEC).  ClinicalTrials.gov identifier NCT04452292. https:\/\/clinicaltrials.gov\/study\/NCT04452292"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-026-04440-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-026-04440-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-026-04440-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:02:27Z","timestamp":1784052147000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-026-04440-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4440"],"URL":"https:\/\/doi.org\/10.1007\/s00428-026-04440-2","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JRN has received consulting fees from Astra-Zeneca and Bayer. For the remaining authors none were declared.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}